Cargando…
Does synaptic hypometabolism or synaptic dysfunction, originate cognitive loss? Analysis of the evidence
Elderly persons with currently normal cognition who have cerebral hypometabolism as shown by low uptake of (18)fluorine‐fluorodeoxyglucose ((18)F‐FDG), are at risk of future loss of cognition and, thus, of future Alzheimer's dementia (AD). Reduction of either (18)F‐FDG or cognition is assumed t...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129845/ https://www.ncbi.nlm.nih.gov/pubmed/34027027 http://dx.doi.org/10.1002/trc2.12177 |
_version_ | 1783694390634479616 |
---|---|
author | Fessel, Jeffrey |
author_facet | Fessel, Jeffrey |
author_sort | Fessel, Jeffrey |
collection | PubMed |
description | Elderly persons with currently normal cognition who have cerebral hypometabolism as shown by low uptake of (18)fluorine‐fluorodeoxyglucose ((18)F‐FDG), are at risk of future loss of cognition and, thus, of future Alzheimer's dementia (AD). Reduction of either (18)F‐FDG or cognition is assumed to reflect synaptic dysfunction, since synapses account for the majority of glucose use by the brain and cognition depends upon accurate synaptic function. The chronology of the connection between reduced cerebral synaptic function and hypometabolism is, therefore, a critical question, because if synaptic dysfunction came first, then correcting the hypometabolism would likely not benefit synaptic function; but if hypometabolism came first, then correcting the hypometabolism probably would benefit synaptic function. That correction might prevent initiation of the cognitive loss that eventuates in AD and, thereby, would benefit the vast numbers of persons in their eighth to tenth decades of life who are at risk for AD. Among the many citations reviewed in this presentation, seven show hypometabolism that precedes synaptic dysfunction, and two show the reverse. Thus the preponderance of evidence, 78%, suggests that the initiating event is synaptic hypometabolism and that it is 3.5‐fold less likely that synaptic dysfunction is the initiator. In addition, it is inherently unlikely that synaptic dysfunction causes hypometabolism. This conclusion could be tested by a clinical trial whose primary objective would be to assess the benefit to cognition of improving synaptic metabolism in patients who are at risk for cognitive loss. |
format | Online Article Text |
id | pubmed-8129845 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81298452021-05-21 Does synaptic hypometabolism or synaptic dysfunction, originate cognitive loss? Analysis of the evidence Fessel, Jeffrey Alzheimers Dement (N Y) Perspective Elderly persons with currently normal cognition who have cerebral hypometabolism as shown by low uptake of (18)fluorine‐fluorodeoxyglucose ((18)F‐FDG), are at risk of future loss of cognition and, thus, of future Alzheimer's dementia (AD). Reduction of either (18)F‐FDG or cognition is assumed to reflect synaptic dysfunction, since synapses account for the majority of glucose use by the brain and cognition depends upon accurate synaptic function. The chronology of the connection between reduced cerebral synaptic function and hypometabolism is, therefore, a critical question, because if synaptic dysfunction came first, then correcting the hypometabolism would likely not benefit synaptic function; but if hypometabolism came first, then correcting the hypometabolism probably would benefit synaptic function. That correction might prevent initiation of the cognitive loss that eventuates in AD and, thereby, would benefit the vast numbers of persons in their eighth to tenth decades of life who are at risk for AD. Among the many citations reviewed in this presentation, seven show hypometabolism that precedes synaptic dysfunction, and two show the reverse. Thus the preponderance of evidence, 78%, suggests that the initiating event is synaptic hypometabolism and that it is 3.5‐fold less likely that synaptic dysfunction is the initiator. In addition, it is inherently unlikely that synaptic dysfunction causes hypometabolism. This conclusion could be tested by a clinical trial whose primary objective would be to assess the benefit to cognition of improving synaptic metabolism in patients who are at risk for cognitive loss. John Wiley and Sons Inc. 2021-05-18 /pmc/articles/PMC8129845/ /pubmed/34027027 http://dx.doi.org/10.1002/trc2.12177 Text en © 2021 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals, Inc. on behalf of Alzheimer's Association. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Perspective Fessel, Jeffrey Does synaptic hypometabolism or synaptic dysfunction, originate cognitive loss? Analysis of the evidence |
title | Does synaptic hypometabolism or synaptic dysfunction, originate cognitive loss? Analysis of the evidence |
title_full | Does synaptic hypometabolism or synaptic dysfunction, originate cognitive loss? Analysis of the evidence |
title_fullStr | Does synaptic hypometabolism or synaptic dysfunction, originate cognitive loss? Analysis of the evidence |
title_full_unstemmed | Does synaptic hypometabolism or synaptic dysfunction, originate cognitive loss? Analysis of the evidence |
title_short | Does synaptic hypometabolism or synaptic dysfunction, originate cognitive loss? Analysis of the evidence |
title_sort | does synaptic hypometabolism or synaptic dysfunction, originate cognitive loss? analysis of the evidence |
topic | Perspective |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129845/ https://www.ncbi.nlm.nih.gov/pubmed/34027027 http://dx.doi.org/10.1002/trc2.12177 |
work_keys_str_mv | AT fesseljeffrey doessynaptichypometabolismorsynapticdysfunctionoriginatecognitivelossanalysisoftheevidence |